Patent status of histone deacetylase inhibitors
- 1 June 2004
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 14 (6) , 791-804
Abstract
Histone deacetylase (HDAC) has emerged as an important therapeutic target for the treatment of cancer and other diseases. Several HDAC inhibitors that target class I and II HDACs are currently in clinical trials. The initial results from these studies indicate that HDAC inhibitors show great promise for the treatment of cancer. To date, more than 30 research organisations are named as applicants on published patent applications claiming structures of HDAC inhibitors. This review summarises the patent literature published from mid-2002 to early 2004 containing claims directed towards HDAC inhibitor structures, together with discussion of the related primary literature.Keywords
This publication has 25 references indexed in Scilit:
- Histone Deacetylase InhibitorsJournal of Medicinal Chemistry, 2003
- Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylationProceedings of the National Academy of Sciences, 2003
- In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylationThe EMBO Journal, 2002
- Histone deacetylase inhibitors: from target to clinical trialsExpert Opinion on Investigational Drugs, 2002
- Current patent status of histone deacetylase inhibitorsExpert Opinion on Therapeutic Patents, 2002
- Deacetylase EnzymesChemistry & Biology, 2002
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and TrapoxinOrganic Letters, 2001
- Histone deacetylase inhibitors as new cancer drugsCurrent Opinion in Oncology, 2001
- Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitorsNature, 1999